NETVision®

(gallium (68Ga) oxodotreotide injection)

This information is intended only for Healthcare Professionals in Canada. Canadian regulations limit the scope of information we can provide to the public for marketed products. If you are a member of the public and have any questions about this product, please consult a qualified healthcare professional for further information.

NETVision® (gallium (68Ga) oxodotreotide injection) is a marketed diagnostic radiopharmaceutical used to non-invasively detect and localize somatostatin receptor (SSTR)-positive neuroendocrine tumours (NETs). The agent is used with positron emission tomography (PET) as an adjunct to other diagnostic tests (e.g. Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI)).

Neuroendocrine tumours (NETs) are the second most common neoplasm of the diffuse endocrine system and are a diverse and uncommon group of malignancies with an incidence of approximately 2 – 6/100,000 in Canada. NETVision® exploits the overexpression of SSTRs as a specific target for diagnostic purposes and for localization of NETs, including in the gastroenteropancreatic tract, respiratory system, thyroid, and presenting as pheochromocytomas and paraganglioma.

Product Information

Indications and Clinical Use

NETVision® (gallium (68Ga) oxodotreotide injection) is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests, for the detection and localization of somatostatin receptor-positive neuroendocrine tumours (NETs).

Description

Route of Administration:

  • Intravenous

Dosage Form/Strength/Composition:

  • Solution for Injection
  • ≤ 122 MBq/mL (radioactive strength at end of synthesis)
  • ≤ 50 μg 68Ga-oxodotreotide peptide (chemical dose)

Non-medicinal Ingredients:

  • Phosphate-buffered saline, ≤ 10% ethanol

Contraindications

  • Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see the NETVision® Product Monograph (Section 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING).
  • Patients who are taking disulfiram (Antabuse)
Privacy Preferences

When you visit our website, it may store information through your browser from specific services, usually in the form of cookies. Here you can change your Privacy preferences. It is worth noting that blocking some types of cookies may impact your experience on our website and the services we are able to offer.

Click to enable/disable Google Analytics tracking code.
Click to enable/disable Google Fonts.
Click to enable/disable Google Maps.
Click to enable/disable video embeds.
Our website uses cookies, mainly from 3rd party services. Define your Privacy Preferences and/or agree to our use of cookies.